Although EpOMEs/DiHOMES [20], [23] and anandamide analogs/receptor agonists [39] have been recently suggested to represent novel therapeutic targets in AKI, our data suggest that future studies on their role in AKI should consider pathways of TRPV1 signaling to understand their molecular actions. Here, TRPV1 is linked to acute kidney injury.